R F Ozols

2.3k total citations
29 papers, 1.4k citations indexed

About

R F Ozols is a scholar working on Reproductive Medicine, Oncology and Molecular Biology. According to data from OpenAlex, R F Ozols has authored 29 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Reproductive Medicine, 11 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in R F Ozols's work include Ovarian cancer diagnosis and treatment (14 papers), Cancer Treatment and Pharmacology (6 papers) and Amino Acid Enzymes and Metabolism (3 papers). R F Ozols is often cited by papers focused on Ovarian cancer diagnosis and treatment (14 papers), Cancer Treatment and Pharmacology (6 papers) and Amino Acid Enzymes and Metabolism (3 papers). R F Ozols collaborates with scholars based in United States, Malaysia and United Kingdom. R F Ozols's co-authors include Robert C. Young, Thomas C. Hamilton, Peter J. O’Dwyer, Robert L. Comis, C McAleer, Corey J. Langer, P F Engstrom, John Leighton, Yechiam Ostchega and Samuel Litwin and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

R F Ozols

28 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R F Ozols United States 17 723 606 250 243 207 29 1.4k
NH Mulder Netherlands 18 644 0.9× 510 0.8× 130 0.5× 59 0.2× 142 0.7× 58 1.1k
S B Howell United States 18 1.0k 1.4× 882 1.5× 181 0.7× 86 0.4× 433 2.1× 31 1.8k
R Plagne France 17 560 0.8× 282 0.5× 144 0.6× 147 0.6× 186 0.9× 100 1.3k
Sharad Ghamande United States 22 770 1.1× 579 1.0× 230 0.9× 476 2.0× 185 0.9× 114 1.7k
Herman Burger Netherlands 28 1.3k 1.8× 1.2k 1.9× 330 1.3× 43 0.2× 128 0.6× 45 2.6k
M Yakushiji Japan 23 417 0.6× 470 0.8× 157 0.6× 772 3.2× 209 1.0× 161 1.7k
G L Scheffer Netherlands 13 1.3k 1.8× 780 1.3× 132 0.5× 72 0.3× 54 0.3× 14 1.7k
G. Dark United Kingdom 14 476 0.7× 558 0.9× 334 1.3× 134 0.6× 111 0.5× 28 1.4k
Edward M. Newman United States 26 1.2k 1.6× 1.1k 1.8× 431 1.7× 50 0.2× 391 1.9× 88 2.4k
Jermaine Coward Australia 23 1.2k 1.7× 704 1.2× 380 1.5× 318 1.3× 221 1.1× 87 2.3k

Countries citing papers authored by R F Ozols

Since Specialization
Citations

This map shows the geographic impact of R F Ozols's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R F Ozols with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R F Ozols more than expected).

Fields of papers citing papers by R F Ozols

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R F Ozols. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R F Ozols. The network helps show where R F Ozols may publish in the future.

Co-authorship network of co-authors of R F Ozols

This figure shows the co-authorship network connecting the top 25 collaborators of R F Ozols. A scholar is included among the top collaborators of R F Ozols based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R F Ozols. R F Ozols is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ozols, R F. (2000). Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.. PubMed. 27(3 Suppl 7). 3–7. 49 indexed citations
2.
Ozols, R F. (1998). Chemotherapy of ovarian cancer. Cancer treatment and research. 11(3). 219–234. 84 indexed citations
3.
Boente, Matthew, Karen A. Yeh, W. Michael Hogan, & R F Ozols. (1996). Current status of staging laparotomy in colorectal and ovarian cancer. Cancer treatment and research. 82. 337–357. 6 indexed citations
4.
O’Dwyer, Peter J., Thomas C. Hamilton, James M. Gallo, et al.. (1996). Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.. Journal of Clinical Oncology. 14(1). 249–256. 140 indexed citations
5.
Schilder, Russell J., et al.. (1995). The management of early ovarian cancer.. PubMed. 9(2). 171–82; discussion 185. 10 indexed citations
6.
Langer, Corey J., John Leighton, Robert L. Comis, et al.. (1995). Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.. Journal of Clinical Oncology. 13(8). 1860–1870. 252 indexed citations
7.
Corn, Benjamin W., et al.. (1994). Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure. Cancer. 74(11). 2979–2983. 41 indexed citations
8.
O’Dwyer, Peter J., Russell J. Schilder, C McAleer, et al.. (1992). Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.. Journal of Clinical Oncology. 10(8). 1352–1358. 21 indexed citations
9.
Reed, Eddie, J Jacob, R F Ozols, Robert C. Young, & Carmen J. Allegra. (1992). 5-fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma. Gynecologic Oncology. 46(3). 326–329. 8 indexed citations
10.
O’Dwyer, Peter J., Joseph Colofiore, John Hoffman, et al.. (1991). Phase I Trial Of Fluorouracil Modulation by N-Phosphonacety-L-aspartate and 6-Methylmercaptopurine Riboside: Optimization of 6-Methylmercaptopurine Riboside Dose and Schedule Through Biochemical Analysis of Sequential Tumor Biopsy Specimens. JNCI Journal of the National Cancer Institute. 83(17). 1235–1240. 13 indexed citations
11.
Reed, E, Yechiam Ostchega, Steven M. Steinberg, et al.. (1990). Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.. PubMed. 50(8). 2256–60. 73 indexed citations
12.
Ozols, R F & Stephen D. Williams. (1989). Testicular cancer. Current Problems in Cancer. 13(5). 289–335. 18 indexed citations
13.
Ozols, R F, et al.. (1989). Effect of Glutathione on DNA Repair in Cisplatin-Resistant Human Ovarian Cancer Cell Lines. JNCI Journal of the National Cancer Institute. 81(7). 535–539. 154 indexed citations
14.
Manetta, Alberto, et al.. (1988). Effect of alpha-difluoromethylornithine (DFMO) on the growth of human ovarian carcinoma.. PubMed. 9(3). 222–7. 7 indexed citations
15.
Lai, Gi‐Ming, et al.. (1988). Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochemical Pharmacology. 37(24). 4597–4600. 135 indexed citations
16.
Rothenberg, Mace L., et al.. (1988). High-Dose Carboplatin With Diethyldithiocarbamate Chemoprotection in Treatment of Women With Relapsed Ovarian Cancer. JNCI Journal of the National Cancer Institute. 80(18). 1488–1492. 37 indexed citations
17.
Hamilton, Thomas C., R F Ozols, & Dan L. Longo. (1987). Biologic therapy for the treatment of malignant common epithelial tumors of the ovary. Cancer. 60(S8). 2054–2063. 16 indexed citations
18.
Fojo, Antonio Tito, Thomas C. Hamilton, Robert C. Young, & R F Ozols. (1987). Multidrug resistance in ovarian cancer. Cancer. 60(S8). 2075–2080. 78 indexed citations
19.
Wu, Ping, R F Ozols, Masakazu Hatanaka, & C W Boone. (1982). Anticancer Drugs: Effect on the Cloning of Raji Lymphoma Cells in Soft Agar. JNCI Journal of the National Cancer Institute. 68(1). 115–21. 7 indexed citations
20.
Ozols, R F, et al.. (1978). Murine ovarian cancer. A model for human disease. Abstr.. The Mouseion at the JAXlibrary (Jackson Laboratory). 234. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by NH Mulder Breakdown of academic impact, for papers by S B Howell Breakdown of academic impact, for papers by R Plagne Breakdown of academic impact, for papers by Sharad Ghamande Breakdown of academic impact, for papers by Herman Burger Breakdown of academic impact, for papers by M Yakushiji Breakdown of academic impact, for papers by G L Scheffer Breakdown of academic impact, for papers by G. Dark Breakdown of academic impact, for papers by Edward M. Newman Breakdown of academic impact, for papers by Jermaine Coward
Rankless by CCL
2026